| Literature DB >> 32856569 |
Helen Counihan1, Ebenezer Baba2, Olusola Oresanya3, Olatunde Adesoro3, Yahya Hamzat3, Sarah Marks1, Charlotte Ward1, Patrick Gimba4, Shamim Ahmad Qazi5, Karin Källander1,6.
Abstract
Current recommendations within integrated community case management (iCCM) programmes advise community health workers (CHWs) to refer cases of chest indrawing pneumonia to health facilities for treatment, but many children die due to delays or non-compliance with referral advice. Recent revision of World Health Organization (WHO) pneumonia guidelines and integrated management of childhood illness chart booklet recommend oral amoxicillin for treatment of lower chest indrawing (LCI) pneumonia on an outpatient basis. However, these guidelines did not recommend its use by CHWs as part of iCCM, due to insufficient evidence regarding safety. We present a protocol for a one-arm safety intervention study aimed at increasing access to treatment of pneumonia by training CHWs, locally referred to as Community Oriented Resource Persons (CORPs) in Nigeria. The primary objective was to assess if CORPs could safely and appropriately manage LCI pneumonia in 2-59 month old children, and refer children with danger signs. The primary outcomes were the proportion of children 2-59 months with LCI pneumonia who were managed appropriately by CORPs and the clinical treatment failure within 6 days of LCI pneumonia. Secondary outcomes included proportion of children with LCI followed up by CORPs on day 3; caregiver adherence to treatment for chest indrawing, acceptability and satisfaction of both CORP and caregivers on the mode of treatment, including caregiver adherence to treatment; and clinical relapse of pneumonia between day 7 to 14 among children whose signs of pneumonia disappeared by day 6. Approximately 308 children 2-59 months of age with LCI pneumonia would be needed for this safety intervention study.Entities:
Keywords: CORPS; Under five; childhood pneumonia; community health worker; oral amoxicillin; research design
Mesh:
Substances:
Year: 2020 PMID: 32856569 PMCID: PMC7480438 DOI: 10.1080/16549716.2020.1775368
Source DB: PubMed Journal: Glob Health Action ISSN: 1654-9880 Impact factor: 2.640
Figure 1.Nigeria map on left with Niger state marked, on right Niger state with two LGAs for chest indrawing pneumonia study.
Figure 2.CORP recruitment: different types on day 0.
Dosing instructions for dispersible amoxicillin [19].
| Age group | Weight | Dose recommendation | Total daily dose |
|---|---|---|---|
| 2 to 11 months | 4 to <10 kg | 1 tab 2 times a day x 5 days | 500 mg |
| 12 to 35 months | 10 to <14 kg | 2 tabs 2 times a day x 5 days | 1000 mg |
| 36 to 59 months | 14 to <19 kg | 3 tabs 2 times a day x 5 days | 1500 mg |
Outline of study procedures including outcome assessment.
| Activity | What | By whom | When | Where | How |
|---|---|---|---|---|---|
| Identification & recruitment of children with chest indrawing | Identification of children aged 2–59 months with chest indrawing and no other danger sign | CORP | Passively through provision of iCCM services | Home, community | iCCM assessment and identification of chest indrawing with no danger signs or other reason to refer |
| Provision of treatment | Oral amoxicillin (50–125 mg/kg) twice a day for 5 days | CORP | After consent obtained for recruitment in the study | Home, community | First dose given by CORP in presence of caregiver. Remainder of doses given by caregiver at home |
| Re-assessment of recruited child and full enrolment | Confirmation of chest indrawing pneumonia and absence of danger signs | RA | RA comes to child’s house within 12 hours of CORP recruitment (contacted by CORP) | Home | RA follows adapted IMCI tool to complete full assessment of child, including use of portable pulse oximeter; according to electronic study job aid application on tablet |
| Supervision and support | Supervision of adherence to study protocol, case confirmation, and follow up of recruited children including those then referred. | RA for CORP, Study coordinator for RAs, Project manager for study coordinator. | Throughout the implementation | At home, community, health facility and hospitals | Accompanied visits, checking of registers, review of treatment cards, observation of administration of treatment, regular meetings and review of reports |
| Process evaluation and Monitoring | All aspects of implementation and its processes to understand if they are conducted as planned | Study team | On a weekly basis by the study team, throughout the implementation | At home, community, health facility and hospital | Review of recruitment forms, treatment cards, reports. Direct observation. |
| Outcome assessment | Clinical treatment failure of chest indrawing pneumonia by day 6 Defined as any of the following: Appearance of a danger signb Hypoxemia (Oxygen saturation ≤90%) Fever and chest indrawing on day 3 Fever or chest indrawing alone on day 6 Change of antibiotic by any health-care provider Death | Initially by RAs and then confirmed by study coordinator and study team | Periodically, throughout the implementation | At home, community, health facility and hospitals | Review of RA-completed electronic enrolment and follow-up forms; follow-up visits by study coordinator of referred children within a day for ascertaining outcome of referral, treatment advised and treatment taken |
| Proportion of children 2–59 months classified with chest indrawing pneumonia who were managed appropriately by CORPs. Defined as Proportion of children enrolled with chest indrawing pneumonia and no other danger signb, who received the correct age-specific dose. Proportion of children with chest indrawing pneumonia and referral sign who were given pre-referral treatment and referred to a health facility. | By RA | During their initial re-assessment of recruited child on day 0 | Home, community, health facility | Re-assessment of child’s symptoms and verification of treatment given. | |
| Proportion of children classified with chest indrawing pneumonia who were followed up by the CORPs on day 3. | RA initially and by study team | From CORP recording form for day 3 visit | |||
| Clinical relapse of pneumonia between day 7 to 14 among children whose signs of pneumonia disappeared by day 6. Defined as: Did not have chest indrawing on day 6 and developed any danger sign, chest indrawing, fever, and/or fast breathing. | RA | Day 15 | Home, community | During re-assessment visit | |
| Adherence to treatment | RA and CORP | Day 6 | Home | Pill count and questionnaire on administration of treatment | |
| Acceptability and satisfaction of caregivers | RA with additional training | Day 6 | Home | Semi-structured interviews with caregivers | |
| Acceptability and satisfaction among CORPs | RA with additional training | Day 15 | Community | Semi-structured interviews with CORPs |
aData and Safety Monitoring Board.
bDanger signs: unable to drink or breastfeed; convulsions; persistent vomiting after ingestion of food or drink; abnormally sleepy or difficult to wake; severe malnutrition.
Follow-up visit schedule for children enrolled.
| 0 | 0–1 | 3 | 6 | 15 | |
|---|---|---|---|---|---|
| Activity | |||||
| Person | CORP | RA | CORP | CORP & RA | RA |
| Outcomes | -CORP performance to classify & manage chest indrawing | -Health status | -Health status | -Health status | |
| Location | CORP | Household | CORP or Household | Household | Household |